MAPC Cell Therapy for Viral ARDS Immune Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Severe COVID-19 cases are characterized by dysregulated hyperinflammatory responses, leading to uncontrolled immune reactions and lung inflammation, which exacerbate the disease pathology and result in conditions like ARDS, where existing treatments are inadequate in modulating these responses effectively.
Innovation Solution
Administration of multipotent adult progenitor cells (MAPCs), specifically the MultiStem® preparation, to patients with moderate to severe ARDS to reduce T cell and monocyte/macrophage activation, promote regulatory T cell differentiation, and induce anti-inflammatory monocyte/macrophage responses, thereby alleviating inflammation and promoting tissue repair.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for severe COVID-19, then standard care is provided, but they are inadequate in modulating hyperinflammatory responses and uncontrolled immune reactions
Solution Approach 1:
The patent introduces multipotent adult progenitor cells (MAPCs) as intermediary cells that mediate between the hyperinflammatory immune response and the need for immune modulation. These MAPCs act as biological mediators that can interact with multiple immune cell types (T cells, monocytes, macrophages) to restore balance, thereby resolving the contradiction between providing standard care and achieving effective immune response modulation.
2Ease of manufacture
If existing therapies are administered, then standard treatment protocols are followed, but they fail to effectively reduce T cell exhaustion and monocyte/macrophage activation
Solution Approach 1:
The patent employs parameter changes by introducing a novel cellular therapy (MAPCs) that fundamentally alters the biological parameters of the immune system. Rather than relying on existing pharmacological parameters that have proven ineffective, the treatment changes the cellular composition and functional parameters of the immune response, enabling effective reduction of T cell exhaustion and monocyte/macrophage activation where conventional therapies failed.
3Device complexity
If no immunomodulatory treatment is given, then treatment simplicity is maintained, but lung inflammation and cytokine storm remain uncontrolled
Solution Approach 1:
The MAPCs serve as intermediary therapeutic agents that bridge the gap between simple supportive care and complex immunomodulatory interventions. By introducing these multipotent cells that can naturally interact with multiple immune cell populations, the treatment provides effective control of lung inflammation and cytokine storm without requiring complex combination therapies or multiple administrative steps, thus resolving the contradiction between treatment simplicity and effectiveness.
Data Source
AI summary
The invention is directed to a method of treating viral-induced acute respiratory distress syndrome (ARDS) by administering to a subject with the virial induced ARDS multipotent adult progenitor cells (MAPCs), which are non-embryonic stem, non-germ cells that have a broad differentiation potential and extended replication capacity. The virus inducing the ARDS can be a Betacoronavirus, such as, severe acute respiratory syndrome (SARS), Corona Virus or Middle East Respiratory Syndrome (MERS), or severe acute respiratory syndrome Corona Virus 2 (SARS-CoV-2).